Here's some very interesting info regarding the treatment therapy Prof Richard Scolyer has undertaken in his (and fellow Aust of the Year, Prof Georgina Long) quest to hopefully prolong his life and gain valuable scientific data on immunotherapy for GBM:-
https://www.practiceupdate.com/journalscan/112467/1/1?elsca1=emc_enews_expert-insight&elsca2=email&elsca3=practiceupdate_onc&elsca4=oncology&elsca5=newsletter&rid=NDQ3MTgxOTYwMzc4S0&lid=20844130
This leads me to this insightful article about Phase 0 trials:-
https://www.clinicaltrialsarena.com/features/glioblastoma-phase-0-trials/?cf-view
What piqued my interest in the above article is the reference to Celgene which Jennifer Chow was with for 6 yrs. She was previously with Roche then after Celgene she worked at Kite. Celgene is now a subsidiary of BSM after the acquisition in Jan 2019.
One would have to be thinking: "Where is Paul Hopper's plan going to ultimately take each of the companies in his stable?"
Here's some very interesting info regarding the treatment...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $12.99M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $949 | 312.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 70 | 67782438 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 91927011 | 27 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |